Janux Therapeutics (JANX) Shares Outstanding (2020 - 2026)

Janux Therapeutics (JANX) has 7 years of Shares Outstanding data on file, last reported at $60.9 million in Q1 2026.

• Shares Outstanding for Q1 2026 came in at $60.9 million, up 2.87% year-over-year; the trailing twelve-month figure through Mar 2026 was $60.9 million (up 2.87% YoY), and the FY2025 annual result was $60.4 million, up 2.23% from the prior year.
• Shares Outstanding rose to $60.9 million in Q1 2026 per JANX's latest filing, from $60.4 million in the prior quarter.
• Over five years, Shares Outstanding peaked at $60.9 million in Q1 2026 and troughed at $5.4 million in Q1 2024.
• A 5-year average of $47.7 million and a median of $46.3 million in 2023 frame the typical range for Shares Outstanding.
• The sharpest annual moves came in 2022 and 2024: Shares Outstanding soared 3273.63% in 2022, then plunged 87.09% in 2024.
• A 5-year view of Shares Outstanding shows it stood at $41.6 million in 2022, then grew by 11.14% to $46.3 million in 2023, then grew by 27.7% to $59.1 million in 2024, then climbed by 2.23% to $60.4 million in 2025, then gained by 0.8% to $60.9 million in 2026.
• Business Quant data shows JANX's Shares Outstanding at $60.9 million in Q1 2026, $60.4 million in Q4 2025, and $60.1 million in Q3 2025.